Metraipolis › archive › dc_3ca71d6e089e

Aliskiren — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Aliskiren
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-08T12:32:51.834Z
SHA-256 of the archived text
0131c3ff3d21cfdb9bc23f039bfc6342e2b5668a503a36134b1084fa530530e4
Stable URL of this page
https://metraipolis.com/documento/dc_3ca71d6e089e

How to cite

Aliskiren — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Aliskiren (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_3ca71d6e089e (Metraipolis archive dc_3ca71d6e089e, sha256 0131c3ff3d21cfdb9bc23f039bfc6342e2b5668a503a36134b1084fa530530e4)
BibTeX
@misc{dc3ca71d6e089e,
  title = {Aliskiren — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Aliskiren},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_3ca71d6e089e; sha256 0131c3ff3d21cfdb9bc23f039bfc6342e2b5668a503a36134b1084fa530530e4},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Aliskiren. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Aliskiren (brand names Tekturna and Rasilez) is the first in a class of drugs called direct renin inhibitors. It is used for essential (primary) hypertension. While used for high blood pressure, other better studied medications are typically recommended due to concerns of higher side effects and less evidence of benefit. In December 2011, Novartis halted a trial of the drug after discovering increased nonfatal stroke, kidney complications, high blood potassium, and low blood pressure in people with diabetes and kidney problems. As a result, in 2012: A new contraindication was added to the product label concerning the use of aliskiren with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) in patients with diabetes because of the risk of kidney impairment, low blood pressure, and high levels of potassium in the blood. A warning to avoid use of aliskiren with ARBs or ACEIs was also added for patients with moderate to severe kidney impairment (i.e., where glomerular filtration rate is less than 60 ml/min). Novartis decided to stop marketing Valturna (aliskiren/valsartan). Aliskiren was co-developed by the Swiss pharmaceutical companies Novartis and Speedel.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Aliskiren» — https://en.wikipedia.org/wiki/Aliskiren
Wikidata Q414904: «primo principio attivo della classe di farmaci noti come inibitori diretti della renina» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q414904
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Aliskiren?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1328952892, consultata il 2026-11-08T12:25:21.540Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: c31f020495438bb3fa50dd85ad40ae9428b100bb6dac12281a13a8924ade0414